ArticleDiabetes, metabolic syndrome and obesity : targets and therapy2025
CD44, ACAN, PLVAP, and HBEGF Emerged as Potential Biomarkers in Diabetic Retinopathy.
Article in Diabetes, metabolic syndrome and obesity : targets and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: DNA methylation was critically involved in the occurrence and development of diabetic retinopathy (DR), but the clinical diagnostic value and mechanism remains unclear. This study aimed to identify and validate the biomarkers associated with DNA methylation in DR. Methods: Public databases provided the data used in this study. The biomarkers associated with DNA methylation in proliferative diabetic retinopathy (PDR) and non-proliferative diabetic retinopathy (NPDR) were identified by differential expression analysis, protein-protein interaction network construction, mendelian randomization, and 2 machine learning algorithms, respectively. Gene set enrichment analysis was utilized to determine the functional roles of these biomarkers. The cell-specific expression patterns of biomarkers were analyzed at the single-cell level. Immune infiltration analysis was performed to further study the relationship between biomarkers, and 28 types of immune cell infiltration. The diagnostic power of biomarkers was assessed by the receiver operating curve (ROC) and nomogram. Results: CD44 was preliminarily identified as a biomarker linked to PDR, whereas ACAN, PLVAP, and HBEGF emerged as biomarkers associated with NPDR. The biomarkers were involved ibosome, lysosome, oxidative phosphorylation, aminoacyl tRNA biosynthesis, P53 signaling pathway, and other pathways. In the retina of diabetic mice, PLVAP and HBEGF were mainly enriched in neutrophils. In the retinal fibroproliferative membranes of PDR patients, CD44 were mainly enriched in monocytes/macrophages. Moreover, CD44 was positively correlated with the remaining differential immune cells except for type 2 T helper cells. Effector memory CD4 T cells showed the strongest positive correlation with ACAN and the largest negative correlation with HBEGF. Finally, the ROC and nomogram validated biomarkers had an excellent diagnostic efficacy. Conclusion: This study identified 4 genes (CD44, ACAN, PLVAP, and HBEGF) associated with DNA methylation may serve as biomarkers of DR, offering new insights into potential therapeutic strategies for DR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.